Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sera PrognosticsSERA -8.10%70 3-1 Month Momentum % is 5.26% as of Aug. 04, 2026. GuruFocus rates SERA with a GF Score™ of 70/100 and a GF Value™ of $1.82 (Fairly Valued). The stock has 5 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Sera Prognostics ranks better than 73% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-04), Sera Prognostics's 3-1 Month Momentum % is 5.26%.
The industry rank for Sera Prognostics's 3-1 Month Momentum % or its related term are showing as below:
SERA's 3-1 Month Momentum % is ranked better than 73% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: -6.115
vs SERA: 5.26
Sera Prognostics (NAS:SERA) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Sera Prognostics 3-1 Month Momentum % Related Terms
SERA vs ZOMDF, OM, LNSR: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Sera Prognostics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sera Prognostics 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Sera Prognostics's 3-1 Month Momentum % falls into.
Sera Prognostics (NAS:SERA) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sera Prognostics (SERA) has a 3-1 Month Momentum % of 5.26% as of Aug. 04, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Sera Prognostics and its competitors. According to the industry distribution chart, Sera Prognostics ranks #230 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 27%.
Is Sera Prognostics' 3-1 Month Momentum % too high?
Sera Prognostics' current 3-1 Month Momentum % is 5.26%. Based on the distribution chart, Sera Prognostics ranks #230 out of 852 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sera Prognostics has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sera Prognostics' 3-1 Month Momentum % compare to ZOMDF and OM?
According to the Medical Devices & Instruments industry distribution chart, Sera Prognostics ranks #230 out of 852 companies for 3-1 Month Momentum %. This puts Sera Prognostics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Sera Prognostics and its competitors. Sera Prognostics's current 3-1 Month Momentum % is 5.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sera Prognostics stock overvalued right now?
Based on GuruFocus' analysis, Sera Prognostics (SERA) is currently considered Fairly Valued. The stock's GF Value™ is $1.82, compared to a current price of $1.93 — trading 6% above its estimated fair value. The current 3-1 Month Momentum % is 5.26%. Sera Prognostics' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Sera Prognostics (SERA), the current 3-1 Month Momentum % is 5.26% as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sera Prognostics (SERA) Overvalued in 2026?
Based on GuruFocus' analysis, Sera Prognostics stock appears to be overvalued.
The current stock price of $1.93 is trading 6% above its estimated GF Value™ of $1.82.
GuruFocus considers Sera Prognostics to be Fairly Valued.
Key valuation signals for SERA:
3-1 Month Momentum %: 5.26%
GF Value™: $1.82 vs. price of $1.93 (6% above fair value)
No single metric tells the full story. See the SERA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
70GF Score
Get the complete analysis for SERA
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SERA has been successfully added to your 
